Literature DB >> 15838376

The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens.

Ryan D Guest1, Robert E Hawkins, Natalia Kirillova, Eleanor J Cheadle, Jennifer Arnold, Allison O'Neill, Joely Irlam, Kerry A Chester, John T Kemshead, David M Shaw, M J Embleton, Peter L Stern, David E Gilham.   

Abstract

Human peripheral blood lymphocytes can be transduced to express antigen-dependent CD3zeta chimeric immune receptors (CIRs), which function independently of the T-cell receptor (TCR). Although the exact function of these domains is unclear, previous studies imply that an extracellular spacer region is required for optimal CIR activity. In this study, four scFvs (in the context of CIRs with or without extracellular spacer regions) were used to target the human tumor-associated antigens carcinoembryonic antigen (CEA), neural cell adhesion molecule (NCAM), the oncofetal antigen 5T4, and the B-cell antigen CD19. In all cases human T-cell populations expressing the CIRs were functionally active against their respective targets, but the anti-5T4 and anti-NCAM CIRs showed enhanced specific cytokine release and cytotoxicity only when possessing an extracellular spacer region. In contrast, the anti-CEA and anti-CD19 CIRs displayed optimal cytokine release activity only in the absence of an extracellular spacer. Interestingly, mapping of the scFv epitopes has revealed that the anti-CEA scFv binds close to the amino-terminal of CEA, which is easily accessible to the CIR. In contrast, CIRs enhanced by a spacer domain appear to bind to epitopes residing closer to the cell membrane, suggesting that a more flexible extracellular domain may be required to permit the efficient binding of such epitopes. These results show that a spacer is not necessary for optimal activity of CIRs but that the optimal design varies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15838376     DOI: 10.1097/01.cji.0000161397.96582.59

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  130 in total

Review 1.  Smart CARs engineered for cancer immunotherapy.

Authors:  Saul J Priceman; Stephen J Forman; Christine E Brown
Journal:  Curr Opin Oncol       Date:  2015-11       Impact factor: 3.645

Review 2.  Strategies for combining immunotherapy with radiation for anticancer therapy.

Authors:  Steven N Seyedin; Jonathan E Schoenhals; Dean A Lee; Maria A Cortez; Xiaohong Wang; Sharareh Niknam; Chad Tang; David S Hong; Aung Naing; Padmanee Sharma; James P Allison; Joe Y Chang; Daniel R Gomez; John V Heymach; Ritsuko U Komaki; Laurence J Cooper; James W Welsh
Journal:  Immunotherapy       Date:  2015-08-27       Impact factor: 4.196

Review 3.  Recent advances and discoveries in the mechanisms and functions of CAR T cells.

Authors:  Rebecca C Larson; Marcela V Maus
Journal:  Nat Rev Cancer       Date:  2021-01-22       Impact factor: 60.716

4.  Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.

Authors:  Haiying Qin; Monica Cho; Waleed Haso; Ling Zhang; Sarah K Tasian; Htoo Zarni Oo; Gian Luca Negri; Yongshun Lin; Jizhong Zou; Barbara S Mallon; Shannon Maude; David T Teachey; David M Barrett; Rimas J Orentas; Mads Daugaard; Poul H B Sorensen; Stephan A Grupp; Terry J Fry
Journal:  Blood       Date:  2015-06-03       Impact factor: 22.113

5.  T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.

Authors:  Eugenia Zah; Meng-Yin Lin; Anne Silva-Benedict; Michael C Jensen; Yvonne Y Chen
Journal:  Cancer Immunol Res       Date:  2016-04-08       Impact factor: 11.151

6.  Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy.

Authors:  Mahesh Jonnalagadda; Armen Mardiros; Ryan Urak; Xiuli Wang; Lauren J Hoffman; Alyssa Bernanke; Wen-Chung Chang; William Bretzlaff; Renate Starr; Saul Priceman; Julie R Ostberg; Stephen J Forman; Christine E Brown
Journal:  Mol Ther       Date:  2014-11-04       Impact factor: 11.454

Review 7.  Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.

Authors:  Michael C Jensen; Stanley R Riddell
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 8.  Design and development of therapies using chimeric antigen receptor-expressing T cells.

Authors:  Gianpietro Dotti; Stephen Gottschalk; Barbara Savoldo; Malcolm K Brenner
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 9.  Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.

Authors:  William R Strohl; Michael Naso
Journal:  Antibodies (Basel)       Date:  2019-07-03

Review 10.  Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.

Authors:  Marc Cartellieri; Michael Bachmann; Anja Feldmann; Claudia Bippes; Slava Stamova; Rebekka Wehner; Achim Temme; Marc Schmitz
Journal:  J Biomed Biotechnol       Date:  2010-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.